Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy.

Published

Journal Article

Patients on chronic intermittent renal replacement therapy (RRT) are at risk for infection with carbapenem-resistant Enterobacteriaceae (CRE). However, the impact of RRT on outcomes after CRE infections remains to be defined. Here we perform a comparison of outcomes for CRE-infected patients with preserved renal function compared with CRE-infected patients on RRT.Cases and controls were defined from a prospective cohort of CRE-infected patients from the Consortium on Resistance against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE). Cases were defined as CRE-infected patients on RRT at hospital admission, while controls were defined as CRE-infected patients with serum creatinine <2 mg/dL and not receiving RRT at admission. Risk factors for 28-day in-hospital mortality were assessed using multivariable logistic regression. An ordinal ranking of outcomes by desirability analysis was performed.Patients on RRT were more likely to have diabetes mellitus and cardiac disease than controls. Urinary sources of infection were less common in the RRT group. In RRT patients, 28-day in-hospital mortality was increased as compared with controls: 22/71 (31%) vs 33/295 (11%). RRT remained significantly associated with 28-day in-hospital mortality after adjustment for source of infection, prehospitalization origin, and severity of illness (adjusted odds ratio, 2.27; 95% confidence interval [CI], 1.09-4.68; P = .03). Using univariable desirability of outcome ranking analysis, RRT status was associated with a 68% (95% CI, 61%-74%) chance of a worse disposition outcome.Chronic RRT in CRE-infected patients is associated with increased in-hospital mortality and worse disposition outcomes at 28 days.

Full Text

Duke Authors

Cited Authors

  • Eilertson, B; Cober, E; Richter, SS; Perez, F; Salata, RA; Kalayjian, RC; Watkins, RR; Doi, Y; Kaye, KS; Evans, S; Fowler, VG; Bonomo, RA; DeHovitz, J; Kreiswirth, B; van Duin, D; Antibacterial Resistance Leadership Group,

Published Date

  • January 2017

Published In

Volume / Issue

  • 4 / 4

Start / End Page

  • ofx216 -

PubMed ID

  • 29181422

Pubmed Central ID

  • 29181422

Electronic International Standard Serial Number (EISSN)

  • 2328-8957

International Standard Serial Number (ISSN)

  • 2328-8957

Digital Object Identifier (DOI)

  • 10.1093/ofid/ofx216

Language

  • eng